Treatment Regimen for Abdominal Tuberculosis

First-Line Treatment Regimen

The American College of Physicians and Infectious Diseases Society of America recommend a 6-month regimen consisting of isoniazid, rifampin, and pyrazinamide for the first 2 months, followed by isoniazid and rifampin for an additional 4 months, for patients with peritoneal or intestinal tuberculosis 1, 2
The initial phase (first 2 months) of treatment should include daily isoniazid, rifampin, pyrazinamide, and ethambutol, according to the Centers for Disease Control and Prevention guidelines 1
Ethambutol should be included in the initial regimen until drug susceptibility results are available, unless there is less than 4% primary resistance to isoniazid in the community, as recommended by the World Health Organization 1

The World Health Organization recommends a 9-month all-oral regimen for fluoroquinolone-susceptible cases of MDR/RR-TB with extrapulmonary involvement 3
A 6-month BPaLM regimen (bedaquiline, pretomanid, linezolid, moxifloxacin) may be used for extrapulmonary TB, according to the International Journal of Infectious Diseases guidelines 3
Longer 18-month individualized regimens are recommended for extensive or complicated cases of MDR/RR-TB, as suggested by the World Health Organization 4

The Centers for Disease Control and Prevention recommend extending treatment to at least 9 months and for at least 6 months beyond documented culture conversion for patients with HIV and abdominal TB 5

Regular clinical assessment for symptom improvement (abdominal pain, fever, weight gain) is recommended, according to the Clinical Infectious Diseases guidelines 1
Radiological follow-up may be necessary to monitor response in peritoneal or intestinal TB, as suggested by the Clinical Infectious Diseases guidelines 2
Directly observed therapy (DOT) is strongly recommended to ensure adherence, according to the Clinical Infectious Diseases guidelines 6

Surgery is generally not required for uncomplicated abdominal TB, according to the Clinical Infectious Diseases guidelines 2
Surgical intervention should be considered only for complications such as intestinal obstruction, perforation, or diagnostic uncertainty, as recommended by the Clinical Infectious Diseases guidelines 1, 2

Adherence to the full 6-month regimen is critical to prevent relapse and development of drug resistance, according to the Clinical Infectious Diseases guidelines 6
Corticosteroid adjunctive therapy is not routinely recommended for abdominal TB due to limited evidence, as suggested by the Clinical Infectious Diseases guidelines 2